TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00650624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
Study: NCT00843050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
Study: NCT03849482

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Fine Needle Aspiration Cytology
Description: Ultrasound-Guided Fine Needle Aspiration Cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Evaluation
Description: Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)

Intervention type: DIAGNOSTIC_TEST
Intervention: Final Histopathological Diagnosis
Description: Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
Study: NCT03589768

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed
Description: Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Description: A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
Study: NCT04263610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) standard scheme
Description: Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
Study: NCT01404130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 0.5-1mg/kg daily for 4-6 months
Study: NCT01846663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, 0 mg BID, 6 months of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin, oral, 550 mg BID, 6 months treatment
Study: NCT03911700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix™ Mesh
Description: Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
Study: NCT02357693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant or placebo will be administered to the patient before surgery
Study: NCT00650624

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth once daily in the morning for 6 weeks
Study: NCT03038334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
Study: NCT02357693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant or placebo will be administered to the patient before surgery
Study: NCT02471274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin
Description: single 400 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin
Description: single 400 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin
Description: single 400 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin
Description: single 400 mg dose
Study: NCT00746239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Escitalopram
Description: Placebo and Escitalopram (5 to 40 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon and Escitalopram
Description: Ramelteon 8 mg and Escitalopram (5-40 mg)
Study: NCT04965948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel food snack
Description: Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo snack
Description: Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
Study: NCT00727142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Insertion of a functioning shunt

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Insertion of a functioning shunt
Study: NCT02444546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given IV
Study: NCT02509572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual health screen (SHS)
Description: Decision support for STI screening through a novel sexual health screen
Study: NCT02563860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: dose escallating
Study: NCT01117740

Intervention type: BEHAVIORAL
Intervention: MDASI Questionnaire
Description: 19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.

Intervention type: BEHAVIORAL
Intervention: MDASI Questionnaire
Description: 19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
Study: NCT04355897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent COVID 19 Plasma
Description: Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
Study: NCT02875483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expedited Scheduling
Description: Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Scheduling
Description: Scheduling of tubal surgery occurs after completion of post-partum office visit
Study: NCT04063709

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Impulse (ARFI) ultrasound
Description: ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Impulse (ARFI) ultrasound
Description: ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Impulse (ARFI) ultrasound
Description: ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Impulse (ARFI) ultrasound
Description: ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
Study: NCT00741637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CholeraGarde®
Description: Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
Study: NCT02988531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
Study: NCT02129725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo capsules, 1 capsule po three times a day for 3 months
Study: NCT02677142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured social skills training program, SSIP
Description: Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CG - social skills activities
Description: Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
Study: NCT01898611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Ghrelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be used as a placebo
Study: NCT04597827

Intervention type: OTHER
Intervention: Metacognition tests
Description: Test on episodic or semantic memory

Intervention type: OTHER
Intervention: Metacognition tests
Description: Test on episodic or semantic memory

Intervention type: OTHER
Intervention: Metacognition tests
Description: Test on episodic or semantic memory
Study: NCT03220516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single use digital ureteroscope
Description: All participants in this arm will undergo RIRS using a single use digital ureteroscope.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reusable fiberoptic ureteroscope
Description: All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reusable digital flexible ureteroscope
Description: All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
Study: NCT03336333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400 mg tablets administered orally once daily.
Study: NCT04263610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) standard scheme
Description: Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) simplified scheme
Description: Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (\>=) 30% at Week 8, no dose increase will be done and if PASI is less than (\<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
Study: NCT02664454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health care organization
Description: Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care
Study: NCT04251585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Novolin R
Description: Intranasal insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Novolin R
Description: Intranasal insulin
Study: NCT04263610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
Study: NCT04251585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Novolin R
Description: Intranasal insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo (0.9% saline)
Study: NCT02899221

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo high dose rate brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia Treatment
Description: Undergo interstitial hyperthermia treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04253106

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Liquid biopsies (blood, gastric fluid).
Description: Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Liquid biopsies (blood, gastric fluid).
Description: Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
Study: NCT02465801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSA-GCSF 1.2 mg
Description: Human Serum Albumin GCSF 1.2mg at day 3 and Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSA-GCSF 1.5 mg
Description: Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCSF
Description: GCSF 5 mcg/kg/day
Study: NCT04106921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Health Coverage Mode
Description: In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month
Study: NCT04441775

Intervention type: OTHER
Intervention: AI-assisted RT modelling
Description: Artificial Intelligence assisted Radiation Treatment
Study: NCT02642952

Intervention type: OTHER
Intervention: non-invasive methods
Description: To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.

Intervention type: OTHER
Intervention: non-invasive methods
Description: To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
Study: NCT04053205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously (IV)
Study: NCT05931354

Intervention type: OTHER
Intervention: HPV test and Pap Smear
Description: HPV test and Pap Smear
Study: NCT03314324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
Study: NCT03965962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg-2
Description: Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRVg-2
Description: Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Inactivated Rabies Vaccine
Description: Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Diploid Cell Vaccine (HDCV)
Description: Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies immune globulin (human)
Description: Pharmaceutical form: Solution for injection;~Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies immune globulin (human)
Description: Pharmaceutical form: Solution for injection;~Route of administration: IM
Study: NCT04568746

Intervention type: PROCEDURE
Group type: OTHER
Intervention: emergency vital room
Description: At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room

Intervention type: PROCEDURE
Group type: OTHER
Intervention: box
Description: patient with score \< 2 will be supported in box
Study: NCT03965962

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies immune globulin (human)
Description: Pharmaceutical form: Solution for injection;~Route of administration: IM
Study: NCT02742324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolotinib
Description: Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-IFN alpha -2a
Description: Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
Study: NCT04120545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrents
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Microcurrents
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents